Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

AZD 7009

Known as: AZD-7009, AZD7009 
 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Organic Chemicals

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Enhancing crystalline properties of a cardiovascular active pharmaceutical ingredient using a process analytical technology based crystallization feedback control strategy.
Pharmaceutical regulatory bodies require minimal presence of solvent in an active pharmaceutical ingredient (API) after… Expand
2009
2009
Rapid Conversion of Persistent Atrial Fibrillation to Sinus Rhythm by Intravenous AZD7009
This randomized, double‐blind trial compared cardioversion rates between AZD7009 infusion (15‐minute 3.25 mg/min, 15‐minute 4.4… Expand
Highly Cited
2007
Highly Cited
2007
Mechanism of Action of the Antiarrhythmic Agent AZD7009
Atrial fibrillation (AF) is the most common tachyarrhythmia in the adult population and is a major cause of morbidity and… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Highly Cited
2007
Highly Cited
2007
Functional effects of the late sodium current inhibition by AZD7009 and lidocaine in rabbit isolated atrial and ventricular tissue and Purkinje fibre.
AZD7009 (tert-Butyl-2-(7-[(2S)-3-(4-cyanophenoxy)-2-hydroxypropyl]-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl)ethylcarbamate) is an… Expand
Highly Cited
2006
Highly Cited
2006
Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009.
BACKGROUND Acute drug conversion of persistent atrial fibrillation usually fails. OBJECTIVES The purpose of this study was to… Expand
2006
2006
Characterization of the In Vivo and In Vitro Electrophysiological Effects of the Novel Antiarrhythmic Agent AZD7009 in Atrial and Ventricular Tissue of the Dog
This study evaluated the effects of the novel antiarrhythmic agent AZD7009 on atrial and ventricular repolarization and on the Na… Expand
Highly Cited
2005
Highly Cited
2005
Blocking Characteristics of hERG, hNav1.5, and hKvLQT1/hminK after Administration of the Novel Anti‐Arrhythmic Compound AZD7009
Introduction: AZD7009 is a novel anti‐arrhythmic compound under development for short‐ and long‐term management of atrial… Expand
2005
2005
Blocking Characteristics of hKv1.5 and hKv4.3/hKChIP2.2 After Administration of the Novel Antiarrhythmic Compound AZD7009
AZD7009 is a novel antiarrhythmic compound in early clinical development for management of atrial fibrillation… Expand
2005
2005
Assessment of the Proarrhythmic Potential of the Novel Antiarrhythmic Agent AZD7009 and Dofetilide in Experimental Models of Torsades De Pointes
Background: This study examined the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide. 
Highly Cited
2004
Highly Cited
2004
Azd7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model.
INTRODUCTION We tested the hypothesis that AZD7009 terminates induced atrial fibrillation (AF) and flutter (AFL) and prevents… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE